ClinicalTrials.gg
RecruitingNCT06207383ABACUSUpdated Dec 6, 2024

Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure

An interventional study of Conduction system pacing and Atrioventricular nodal ablation in Atrial Fibrillation, Persistent and Heart Failure, sponsored by University Hospital, Geneva. Recruiting at 18 sites in 14 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 117 studies in Atrial Fibrillation with a site in Switzerland — 23 open to participants now, 33 under way, 1 of them phase 3. Atrial Fibrillation · Switzerland.

Planned enrollment
46th of 70
220 · median 409
Started
2024
with 3 others
No phase
31 of 117
7 open now
Primary completion
2028-06
later than 21 of 32 live
Registered
103rd of 117
by date

Among the 117 studies in Atrial Fibrillation with a site in Switzerland, this one is the 46th largest by planned enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2024, is one of 31 with no phase, reaches primary completion later than 21 of the 32 other live ones, and was the 103rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

23 of the 117 studies in Atrial Fibrillation with a site in Switzerland are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Atrial Fibrillation with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate two treatment strategies in patients with chronic atrial fibrillation and heart failure, who are eligible for atrial fibrillation ablation. Patients will be randomized to either atrial fibrillation ablation or to implantation of a pacemaker with conduction system pacing followed by atrioventricular node ablation. The effect of treatment allocation on total mortality, cardiovascular hospitalization and heart failure hospitalization will be compared.

Read the detailed description

Aim To compare clinical outcome with a strategy of conduction system pacing and atrioventricular nodal ablation (CSP+AVNA), versus atrial fibrillation (AF) ablation by pulmonary vein isolation (PVI) in patients with persistent atrial fibrillation (AF) and heart failure (HF), to guide future management of these patients.

Hypotheses

  1. CSP+AVNA is superior to AF ablation in patients with persistent AF and HF for reducing mortality and cardiovascular hospitalization.
  2. CSP+AVNA is non-inferior to AF ablation in patients with persistent AF for reducing mortality and heart failure hospitalization.

Design Investigator-initiated, prospective randomized, controlled, open-label, multicentre study conducted in \~ 30 centres from 14 countries in Europe with expertise in CSP and AF ablation.

Sample size 220 patients

Study duration 4 years

03

Conditions studied

  • Atrial Fibrillation, Persistent
  • Heart Failure
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(i) Persistent AF with symptomatic HF despite medical therapy, considered to be suitable for AF ablation, with at most one previous PVI procedure.

(ii) At least one prior hospital admission, or emergency room / HF clinic visit for HF in the past 2 years, with NT-pro-BNP > 1000 pg/ml or BNP > 250 pg/ml measured at any timepoint during this interval.

(iii) Previous or current rate or rhythm control drug therapy. (iv) Age > 60 years

Exclusion criteria

Exclusion Criteria:

(i) Class IV and systolic blood pressure ≤80 mmHg despite optimized therapy.

(ii) \< 2 years. (iii) Need for major surgical intervention. (iv) Myocardial infarction, stroke or PCI within the previous 3 months. (v) Previously implanted or planned implantation of CRT device or pacemaker. Implantable cardioverter defibrillator (ICD) implantation without a pacing indication is acceptable.

(vi) Participation in another controlled trial. (vii) Inability to sign and form.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Other
    Atrial fibrillation ablation

    Catheter ablation of atrial fibrillation using technique at the investigator's discretion but including pulmonary vein isolation as an endpoint.

    Procedure: Atrial fibrillation ablation

  • Active comparator
    Conduction system pacing + atrioventricular nodal ablation

    Conduction system pacing (either His bundle pacing or left bundle branch area pacing) with catheter ablation of the atrioventricular node.

    Device: Conduction system pacing · Procedure: Atrioventricular nodal ablation

Interventions

  • DeviceConduction system pacing

    Conduction system pacing (either His bundle pacing or left bundle branch area pacing)

  • ProcedureAtrioventricular nodal ablation

    Catheter ablation of the atrioventricular node

  • ProcedureAtrial fibrillation ablation

    Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)

06

What researchers measure

Primary outcomes

  1. Superiority endpoint

    Incidence of mortality and cardiovascular hospitalization in each arm

    Time frame: 1-4 years

  2. Non-inferiority endpoint

    Incidence of mortality and heart failure hospitalization in each arm

    Time frame: 1-4 years

Secondary outcomes

  1. Minnesota Living with Heart Failure quality of life measure

    The questionnaire is comprised of 21 questions around physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. The patient marks a 0-5 scale to indicate the extent to which each itemized adversity of heart failure has prevented the patient from living as they wanted to live during the past 4 weeks. The questionnaire is scored by summation of all 21 responses (the higher the score, the worse the quality of life).

    Time frame: 1 year

  2. Left ventricular ejection fraction

    Measurement using echocardiography

    Time frame: 1 year

  3. Complications

    Peri-procedural and long-term

    Time frame: 1-4 years

  4. NYHA class

    New York Heart Association classification of heart failure symptoms

    Time frame: 1-4 years

  5. Cost-Effectiveness Analysis

    Evaluation of clinical outcomes and associated costs between between the study arms. This evaluation will be conducted from a societal perspective, capturing both the direct medical costs and the broader societal impacts of the interventions.

    Time frame: 1-4 years

07

Study locations

5 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data repository

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After study closure

Access criteria: Request to study P.I.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2028, 44 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 44 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2023
First posted
Jan 17, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06207383
Collaborators
Swiss National Science Foundation
Responsible party
Haran Burri, MD (Chief Investigator and Sponsor Representative, University Hospital, Geneva) — Principal investigator
First posted
Jan 17, 2024
Start date
Oct 1, 2024
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 6, 2024

Study contacts

Haran Burri
Contact
haran.burri@hcuge.ch
+41794616217
Nikola Kozhuharov
Contact
nikola.kozhuharov@googlemail.com
+41764439086

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion